Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 9/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.36 |
| ▸ | RXRA | P19793 | 5/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14650742 | 0.88 | PRCP (0.58) | PRCPGRM5 | |
| SCHEMBL14650767 | 0.82 | PRCP (0.51) | PRCPNR1H2GRM5JAK2JAK1 | |
| SCHEMBL15894619 | 0.76 | PRCP (0.54) | PRCP | |
| SCHEMBL14650770 | 0.76 | PRCP (0.66) | PRCP | |
| SCHEMBL15894636 | 0.73 | PRCP (0.63) | PRCP | |
| SCHEMBL14650828 | 0.72 | PRCP (0.79) | PRCP | |
| SCHEMBL15894613 | 0.71 | PRCP (0.66) | PRCP | |
| SCHEMBL12175462 | 0.71 | PRCP (0.58) | PRCP | |
| SCHEMBL14650782 | 0.69 | JAK2 (0.39) | NR1H2RXRANR1H3GRM5KDM1A | |
| SCHEMBL30623411 | 0.69 | GRM5 (0.37) | NR1H2RXRANR1H3GRM5KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, PEPD | PRCP 1/4885NR1H2 1429/4885RXRA 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.